Psoriasis biologics comparison

Dermatology

Compare biologic therapies for moderate-to-severe plaque psoriasis. Modern IL-17 and IL-23 inhibitors offer high skin clearance rates. Choice depends on insurance formulary position, mechanism preference, and dosing convenience.

Select any two to compare side by side

All products in this comparison

ProductManufacturerRouteFrequencyKey difference
SkyriziAbbVieSC injectionEvery 12 weeks (after loading)IL-23 inhibitor; highest PASI 90/100 rates; extended dosing interval
TremfyaJanssenSC injectionEvery 8 weeks (after loading)IL-23 inhibitor; also approved for PsA
CosentyxNovartisSC injectionEvery 4 weeks (after loading)IL-17A inhibitor; approved for psoriasis, PsA, and AS
TaltzEli LillySC injectionEvery 4 weeks (after loading)IL-17A inhibitor; rapid onset of action
StelaraJanssenSC injectionEvery 12 weeks (after loading)IL-12/23 inhibitor; long track record; biosimilars available
HumiraAbbVieSC injectionEvery 2 weeksTNF inhibitor; biosimilars widely available; more frequent dosing
SotyktuBMSOral (tablet)DailyOral TYK2 inhibitor; no injection required; newer agent
OtezlaAmgenOral (tablet)Twice dailyOral PDE4 inhibitor; no immunosuppression; lower efficacy than biologics

Related guides

Denied one of these medications?

Ellen can decode your denial letter, identify why you were denied, and generate a personalized appeal, free for patients.